 Associations of melatonin receptor gene polymorphisms with Graves’ disease

Jiunn-Diann Lin1,2,3☯, Shun-Fa Yang4,5☯, Yuan-Hung Wang1,6, Wen-Fang Fang7, Ying-Chin Lin7, Bing-Chun Liou1, Yuh-Feng Lin1,8, Kam-Tsun Tang9, Chao-Wen Cheng1*  

1 Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan, 2 Division of Endocrinology, Department of Internal Medicine, Shuang-Ho Hospital, Taipei Medical University, New Taipei City, Taiwan, 3 Division of Endocrinology and Metabolism, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan, 4 Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan, 5 Department of Medical Research, Chung Shan Medical University Hospital, Taichung, Taiwan, 6 Department of Medical Research, Shuang-Ho Hospital, Taipei Medical University, New Taipei City, Taiwan, 7 Department of Family Medicine, Shuang-Ho Hospital, Taipei Medical University, New Taipei City, Taiwan, 8 Division of Nephrology, Department of Internal Medicine, Shuang-Ho Hospital, Taipei Medical University, New Taipei City, Taiwan, 9 Division of Endocrinology and Metabolism, Department of Internal Medicine Taipei Veterans General Hospital, Taipei, Taiwan  

☯ These authors contributed equally to this work.  
* ccheng@tmu.edu.tw

Abstract

Background
Melatonin plays an important role in immunity and has been linked to autoimmune diseases. Possible associations of single-nucleotide polymorphisms (SNPs) of melatonin receptor type 1A (MTNR1A) and 1B (MTNR1B), with autoimmune thyroid disease in an ethnic Chinese (i.e., Taiwanese) population were examined.

Materials and methods
Totally, 83 Hashimoto’s thyroiditis patients, 319 Graves’ disease (GD), and 369 controls were recruited. Three SNPs (rs6553010, rs13140012, and rs2119882) of MTNR1A and three SNPs (rs1387153, rs10830963, and rs1562444) of MTNR1B were genotyped.

Results
There were a reduced frequency of the C allele of rs2119882 and a reduced percentage of the CC+CT genotype in the GD group compared to the control group ($p=0.039$, odds ratio (OR) = 0.79, 95% confidence interval (CI) = 0.63~0.99, and $p=0.032$, OR = 0.72, 95% CI = 0.53~0.97, respectively). There was a significant difference in the percentage of the AT haplotype of the combination of rs13140012 and rs2119882 between the GD and control groups ($p=0.010$, OR = 1.34, 95% CI = 1.07~1.67). In addition, there were significant associations of anti-thyroid peroxidase antibody titers with rs13140012 and rs2119882, and the AATT genotype of the combination of rs13140012 and rs2119882 ($p=0.003$, 0.003, and 0.004, respectively). There were no significant associations of SNPs and possible haplotypes of MTNR1B with susceptibility to GD.
Conclusions

Genetic variants of rs2119882 of MTNR1A and the AT haplotype of the combination of rs2119882 and rs13140012 were associated with GD susceptibility in an ethnic Chinese population. The results support the involvement of the melatonin pathway in the pathogenesis of GD.

Introduction

Melatonin exerts multiple biological functions, including promoting sleep, regulating circadian and seasonal rhythms, promoting anti-aging, antioxidation, anti-tumorigenesis, and anti-apoptosis, eliminating free radicals, and controlling the onset of puberty [1,2,3,4]. In addition, evidence shows that melatonin plays a critical role in regulating both innate and adaptive immune responses and the balance of T-helper 1/T-helper 2 cytokines [5,6]. Melatonin deprivation and exogenous melatonin administration can induce immune dysregulation [7,8]. Moreover, melatonin is even considered to be the third signal triggering an immune response together with the human leukocyte antigen-processed antigen-T cell receptor and costimulatory molecule expressions [9]. Because of its strong immunoregulatory function, melatonin has been linked to several autoimmune diseases, including systemic lupus erythematosus, multiple sclerosis, type 1 diabetes mellitus, rheumatoid arthritis, and inflammatory bowel disease [10,11].

In humans, two major types of melatonin receptor (MTNR) genes, the MTNR1A gene, encoding MT1, and the MTNR1B gene, encoding MT2, were identified, and their genetic variants were linked to several diseases [12,13]. Genetic variants of MTNR1A were linked to tumor formation, coronary artery disease, scoliosis, etc. [14,15,16]. On the other hand, single-nucleotide polymorphisms (SNPs) of MTNR1B were reported to be associated with glucose intolerance, cardiovascular diseases, systemic lupus erythematosus, and rheumatoid arthritis [17,18]. It was also reported that melatonin can bind to MTNRs of immunocytes, control the downstream intracellular signaling pathway, and subsequently directly modulate immune reactions [19,20].

The potential association between melatonin and thyroid functions was described in previous studies. Lewinski et al. showed that melatonin can repress mitosis of thyroid follicular cells in vivo and in a cell culture system [21]. Wright et al. indicated that the administration of melatonin directly suppressed thyroid hormone secretion [22,23]. However, Gordon et al. demonstrated that there was no significant change in circulating thyroid hormone levels but an increased total thyroid hormone (T4) content in the thyroid gland in male weanling rats with chronic melatonin intake compared to controls [24]. Interestingly, recent evidence showed that melatonin, its key enzymes required for melatonin synthesis, and the MT1 receptor protein are present in the thyroid gland, which suggests that melatonin can also influence thyroid-specific gene expressions, and thyroid hormone synthesis and regulation [25].

Autoimmune thyroid disease (AITD) consists of a spectrum from Graves’ disease (GD) with high thyroid function to Hashimoto’s thyroiditis (HT) with declined thyroid function. GD is mainly driven by humoral immunity, which results in the formation of a pathogenic thyroid-stimulating hormone (TSH) receptor antibody (TSHRAb). The TSHRAb binds to TSH receptors of thyroid follicular cells and subsequently stimulates hyperplasia in thyroid follicular cells, enhances thyroid-specific gene expressions, and increases thyroid hormone synthesis. On the other hand, HT is mainly derived from cell-mediated immune reactions, which
induce thyroid follicular cell apoptosis, increase lymphocyte infiltration into the thyroid gland, destroy thyroid follicles, and finally reduce thyroid function [26].

It is well established that AITD results from interactions of genetic susceptibility and environmental factors, which lead to a breakdown in immune tolerance [26]. Tang et al. suggested that melatonin can alleviate oxidative stress and reduce DNA damage of lymphocytes of GD patients in vitro [27]. In our previous study, we found a possible association of genetic variants of B-cell-activating factor with the occurrences of GD and AITD, and production levels of an autoantibody [28]. In addition, melatonin was reported to be able to offset BAFF overexpression in cells of systemic lupus erythematosus patient [29]. This evidence further implies potential regulatory mechanisms of melatonin on autoantibody production. As the melatonin-MTNR signaling pathway is associated with immune regulation, autoimmune diseases, and the thyroid gland itself, it is not surprising that the melatonin-MTNR signal may also play certain roles in AITDs. However, no study has yet been conducted to investigate the impact of the melatonin-MTNR pathway on AITDs. In this study, we further explored possible associations of SNPs of MTNR1A and MTNR1B with AITDs in an ethnic Chinese (i.e., Taiwanese) population.

**Materials and methods**

**Subjects**

As in our previously published article [28], blood specimens were obtained by the Division of Endocrinology, Shuang-Ho Hospital from January 2013 to September 2014, including 319 patients with GD and 83 patients with HT. In addition, 369 blood samples of subjects without AITD or other autoimmune diseases were collected from the Health Screening Center of Shuang-Ho Hospital in May to August 2014. The study protocol was approved by the Taipei Medical University-Joint Institutional Review Board. Written informed consent was obtained from all subjects before participation. All enrolled participants were older than 20 years. Pregnant women and subjects with a history of intoxication or alcoholism were excluded. GD and HT were determined according to the criteria as previously described [28].

**Genotyping**

SNPs were differentiated using the Taqman assay and were subsequently determined by Sequence Detection System vers. 3.0 software (Applied Biosystems, Foster City, CA). A real-time polymerase chain reaction was performed by adding 10 ng of DNA to the buffer, containing 5 μL of MasterMix, 0.25 μL of a probe, and 1 μL each of the forward and reverse primers, in a total volume of 10 μL. The mixtures were amplified in the Applied Biosystems Step-one Real-time Polymerase Chain Reaction system according to manufacturer’s protocol. Information on the SNPs is given in Table A in S1 File.

**Laboratory analysis**

Serum free thyroxine (FT4), TSH, anti-thyroid peroxidase antibody (anti-TPO Ab), and anti-thyroglobulin antibody (ATA) titers were measured as previously described [30].

**Statistical analysis**

SPSS vers. 13.0 for Windows (SPSS, Chicago, IL) was used for all statistical analyses. Quantitative values are shown as the mean ± standard deviation (SD). An independent t-test was used to compare differences in demographic data, FT4, TSH, and TSHRAb between the two groups. A χ² test was used to assess differences in the GD, HT, or AITD groups with the control group.
Comparisons of clinical parameters among the GD, HT, and control groups were performed by a one-way analysis of variance analysis with Bonferroni’s post-hoc tests. A test of Hardy-Weinberg equilibrium was performed with the $\chi^2$ test. The $\chi^2$ test or Fisher’s exact test was also used to assess differences in categorical data between the two groups.

We initially assessed associations of the susceptibility to GD, HT, or AITD with demographic parameters and SNPs using a univariate logistic regression. Significant distinguishing factors were determined and were further analyzed by a multivariate logistic regression. Pairwise linkage disequilibrium and associations of haplotypes with susceptibility to GD, HT, and AITD were investigated using Haploview software vers. 4.2. All statistical tests were two-sided, and a $p$ value of $<0.05$ was considered significant.

**Results**

**Demographic data of the GD, HT, AITD, and control groups**

Table B in S1 File presents demographic data of the enrolled HT, GD, AITD, and control groups. Patients with HT were older than the healthy controls. Meanwhile, a higher prevalence of females was observed in the HT than in the GD and control groups. A higher percentage of patients with GD had a smoking habit than in the control group. Patients in both the GD and HT groups had higher prevalences of a family history of thyroid disease than did patients in the control group.

**Associations of SNPs of MTNR1A and MTNR1B with susceptibility to AITD**

The linkage disequilibrium blocks of three SNPs of the MTNR1A gene and three SNPs of the MTNR1B gene are shown in Fig 1A and 1B, respectively. Genotype frequencies of the three SNPs of MTNR1A (rs6553010, rs13140012, and rs2119882) and the three SNPs of MTNR1B (rs1387153, rs10830963, and rs1562444) were determined in all groups (Tables 1 and 2), and all of them exhibited Hardy-Weinberg equilibrium (data not shown). As MTNR1B SNPs have been linked to glucose intolerance, subjects without hyperglycemia (GD = 15, HT = 1, healthy controls = 60) and all subjects without excluding glucose intolerance were both analyzed in the MTNR1B association study. Differences in genotypic and allelic frequencies of the SNPs of MTNR1A in the GD, HT, AITD, and control groups were compared, and results are shown in Table 1. There were significantly lower frequencies of the C allele of rs2119882 in the GD group than in the control group (Table 1). Meanwhile, there was a reduced percentage of the CC+CT genotype in the GD ($p = 0.032$) group compared to the control group (Table 1). There was no significant difference in the frequency of the T allele of rs13140012 between the GD and control groups ($p = 0.062$). Besides, there was no significant difference in the percentage of the AT+TT genotype in rs13140012 between the GD ($p = 0.069$) and control groups. There were no significant differences in allelic or genotypic frequencies of rs6553010 between GD and control groups (Table 1) in addition, there were no significant differences in allelic or genotypic percentages of all three SNPs of MTNR1B between the GD and control groups, between the HT and control groups, or between the AITD and control groups whether analyzing only those without glucose intolerance or all participants (Table 2 and Table C in S1 File, respectively). Finally, to determine differences in genetic effects on the susceptibility to GD in different genders, we respectively evaluated the association of genetic variants of MTNR1A with GD in females and males, and results are shown in Table D in S1 File. There were no associations of the three MTNR1A SNPs with GD in females, while there were significant decreases
in the T allele and TT genotype in rs13140012 in the GD group compared to the control group in males \( (p = 0.044 \text{ and } 0.044, \text{ respectively, Table D in S1 File}) \).

**Associations of haplotypes of MTNR1A and MTNR1B with the GD, HT, AITD, and control groups**

We further investigated possible haplotypes of rs13140012, rs6553010, and rs2119882 of MTNR1A for susceptibility to GD, HT, and AITD. We initially analyzed haplotypes of the combination of rs6553010, rs13140012, and rs2119882 of MTNR1A, and results are shown in Table E in S1 File. We found that the CTA haplotypes of rs2119882, s13140012, and rs6553010 reported by Lin et al., which are associated with susceptibility to oral cancer, did not contribute to susceptibility to GD \[31\]. However, due to the relatively low D' value between rs6553010 and rs2119882 \( (D' = 0.58 < 0.7) \) \[32\], we mainly focused on the rs13140012 and rs2119882 haplotypes \( (D' = 0.80) \) in the current study (Fig 1A and Table 3). In MTNR1A, rs13140012 and rs2119882 exhibited high linkage disequilibrium in the GD and control groups \( (D' = 0.80) \). The most common haplotype was AT, followed by TC, TT, and AC in the GD, HT, AITD, and control groups. There was a significant difference in the AT frequency between the GD and control groups \( (p = 0.010) \). These findings suggest that the AT haplotypes of rs13140012 and rs2119882 were associated with susceptibility to GD. On the contrary, no significant association of TC, TT, or AC haplotypes with the GD, HT, or AITD groups was observed (Table 3).

Possible haplotypes of rs1387153, rs10830963, and rs1562444 of MTNR1B were also explored, and results are shown in Table F in S1 File. The most prevalent haplotype was TGA, followed by CCG, CCA, and CGA. There were no significant differences in the frequencies of these haplotypes between the GD and control groups, between the HT and control groups, or between the AITD and control groups.
Associations of SNPs of MTNR1A and MTNR1B with thyroid function, and TSHRAb and anti-TPO Ab titers at the baseline in the GD, HT, and AITD groups

There were no significant associations of the severity of GD or HT with these six SNPs (data shown in Table G in S1 File). TSHRAb titers at the baseline in patients also showed no significant association in the GD group with genotypes of rs6553010, rs13140012, or rs2119882 of MTNR1A ($p = 0.357$, 0.295, and 0.160, Fig A1, A2 and A3 in S1 File, respectively). At the same time, there was no significant difference in baseline TSHRAb levels between the AATT and non-AATT genotypes of rs13140012 and rs2119882 ($p = 0.302$, Fig A4 in S1 File). Similarly, there was no association of TSHRAb levels with genotypes of the three SNPs and their combined genotypes of MTNR1B (data not shown).

There was no significant difference in the frequency of the AA genotype of rs6553010 between the high-anti-TPO group and that in low-anti-TPO group in patients with GD at the baseline ($p = 0.083$, Fig 2A). In contrast, there were significant associations of anti-TPO Ab titers with rs13140012 and rs2119882 ($p = 0.003$ and 0.003, Fig 2B and 2C, respectively). At the same time, there was also a higher percentage of the AATT genotype with the combination of

**Table 1. Genotypic and allelic frequencies of rs13140012, rs6553010, and rs2119882 in the melatonin receptor type 1A gene.**

| Polymorphism | Control n (%) | GD n (%) | HT n (%) | AITD n (%) | OR1 (95% CI) | OR2 (95% CI) | OR3 (95% CI) |
|--------------|---------------|----------|----------|------------|--------------|--------------|--------------|
| rs6553010    |               |          |          |            |              |              |              |
| AA           | 159 (45.3)    | 162 (50.9) | 30 (36.1) | 192 (47.8) | 1            | 1            | 1            |
| AG           | 149 (42.5)    | 120 (31.7) | 39 (47.0) | 159 (39.7) | 0.79 (0.57–0.90) | 1.39 (0.82–2.35) | 0.83 (0.65–1.20) |
| GG           | 43 (12.3)     | 36 (11.3)  | 14 (16.9) | 50 (12.5)  | 0.82 (0.50–1.35) | 2.34 (0.24–22.7) | 0.96 (0.61–1.52) |
| AG+GG        | 192 (54.8)    | 156 (43.0) | 53 (63.9) | 209 (52.2) | 0.80 (0.59–1.08) | 1.46 (0.89–2.40) | 0.90 (0.68–1.20) |
| Allele       |               |           |          |            |              |              |              |
| A            | 467 (66.5)    | 444 (69.8) | 99 (60.7) | 543 (67.7) | 1            | 1            | 1            |
| G            | 235 (33.5)    | 192 (30.2) | 67 (39.3) | 259 (32.3) | 0.86 (0.68–1.08) | 1.35 (0.95–1.90) | 0.95 (0.76–1.18) |
| rs13140012   |               |          |          |            |              |              |              |
| AA           | 140 (39.9)    | 149 (46.9) | 26 (31.3) | 175 (43.6) | 1            | 1            | 1            |
| AT           | 165 (47.0)    | 136 (42.8) | 46 (55.4) | 182 (45.4) | 0.77 (0.56–1.07) | 1.50 (0.88–2.55) | 0.88 (0.65–1.20) |
| TT           | 46 (13.1)     | 33 (10.4)  | 11 (13.3) | 44 (11.0)  | 0.67 (0.41–1.12) | 1.29 (0.59–1.81) | 0.73 (0.46–1.17) |
| AT+TT        | 201 (60.1)    | 169 (53.2) | 57 (68.7) | 216 (56.4) | 0.75 (0.55–1.02) | 1.46 (0.87–2.42) | 0.85 (0.64–1.14) |
| Allele       |               |           |          |            |              |              |              |
| A            | 445 (63.4)    | 434 (68.2) | 98 (59.0) | 532 (66.3) | 1            | 1            | 1            |
| T            | 257 (36.6)    | 202 (31.8) | 68 (41.0) | 270 (33.7) | 0.81 (0.64–1.01) | 1.20 (0.85–1.70) | 0.87 (0.70–1.07) |
| rs2119882    |               |          |          |            |              |              |              |
| TT           | 140 (39.9)    | 153 (48.1) | 28 (33.7) | 181 (45.1) | 1            | 1            | 1            |
| CT           | 166 (47.3)    | 132 (41.5) | 43 (51.8) | 175 (43.6) | 0.73 (0.53–1.01) | 1.30 (0.77–2.19) | 0.82 (0.60–1.11) |
| CC           | 45 (12.8)     | 33 (10.4)  | 12 (14.5) | 45 (11.2)  | 0.67 (0.41–1.11) | 1.33 (0.63–2.84) | 0.77 (0.48–1.24) |
| CC+CT        | 211 (60.1)    | 165 (51.9) | 55 (66.3) | 220 (54.8) | 0.72 (0.53–0.97) | 1.30 (0.79–2.76) | 0.81 (0.60–1.08) |
| Allele       |               |           |          |            |              |              |              |
| T            | 446 (63.5)    | 438 (68.9) | 99 (60.7) | 537 (67.0) | 1            | 1            | 1            |
| C            | 256 (36.5)    | 198 (31.1) | 67 (39.3) | 265 (33.0) | 0.79 (0.63–0.99) | 1.18 (0.83–1.67) | 0.86 (0.70–1.06) |

GD, Graves’ disease; HT, Hashimoto’s thyroiditis; AITD, autoimmune thyroid disease (GD + HT); control, control group. OR1, odds ratio 1, GD vs. the control; OR2, odds ratio 2, HT vs. the control; OR3, odds ratio 3, AITD vs. the control; CI, confidence interval

*$p < 0.05.$

[https://doi.org/10.1371/journal.pone.0185529.t001](https://doi.org/10.1371/journal.pone.0185529.t001)
rs13140012 and rs2119882 in the high anti-TPO group than that in low anti-TPO group in patients with GD (Fig 2D, \( p = 0.004 \)).

**Multivariate logistic regression analysis of SNPs of MTNR1A for susceptibility to GD**

Demographic characteristics, such as age, sex, a family history of thyroid disease, and smoking, were first included in the univariate analysis to predict the occurrence of GD. Significant factors, in conjunction with rs6553010, rs13140012, and rs2119882 of MTNR1A and the AATT genotype of rs13140012 and rs2119882, were analyzed by a multivariate logistic regression.

**Table 2. Genotypic and allelic frequencies of rs1387153, rs10830963, and rs1562444 in the melatonin receptor type 1B gene.**

| Polymorphism | Controln (%) | GDrn (%) | HTnr (%) | AITDn (%) | OR1 (95% CI) | OR2 (95% CI) | OR3 (95% CI) |
|--------------|--------------|----------|----------|-----------|--------------|--------------|--------------|
| rs1387153    |              |          |          |           |              |              |              |
| CC           | 101 (33.8)   | 93 (30.7)| 27 (32.9)| 120 (31.2)| 1            | 1            | 1            |
| CT           | 137 (45.8)   | 149 (49.2)| 43 (52.4)| 192 (49.9)| 1.18 (0.82–1.70)| 1.17 (0.68–2.03)| 1.18 (0.84–1.66)|
| TT           | 61 (20.4)    | 61 (20.1)| 12 (14.6)| 73 (18.9)| 1.09 (0.69–1.71)| 0.74 (0.35–1.56)| 1.01 (0.66–1.55)|
| CT+TT        | 198 (66.2)   | 156 (69.3)| 55 (67.0)| 265 (68.8)| 1.15 (0.82–1.62)| 1.04 (0.62–1.75)| 1.13 (0.82–1.56)|
| Allele       |              |          |          |           |              |              |              |
| C            | 339 (56.7)   | 335 (55.3)| 97 (59.1)| 432 (56.1)| 1            | 1            | 1            |
| T            | 259 (43.3)   | 271 (44.7)| 67 (40.9)| 338 (43.9)| 1.06 (0.84–1.33)| 0.90 (0.64–1.28)| 1.02 (0.83–1.27)|
| rs10830963   |              |          |          |           |              |              |              |
| CC           | 96 (32.1)    | 91 (30.0)| 25 (30.4)| 116 (30.1)| 1            | 1            | 1            |
| CG           | 147 (49.2)   | 143 (47.2)| 44 (53.7)| 187 (48.6)| 1.03 (0.71–1.48)| 1.15 (0.66–2.00)| 1.05 (0.75–1.49)|
| GG           | 56 (18.7)    | 69 (22.8)| 13 (15.9)| 82 (21.3)| 1.30 (0.83–2.05)| 0.89 (0.42–1.88)| 1.21 (0.79–1.87)|
| CG+GG        | 203 (77.9)   | 169 (70.0)| 57 (69.6)| 269 (69.9)| 1.10 (0.78–1.56)| 1.08 (0.64–1.83)| 1.10 (0.79–1.52)|
| Allele       |              |          |          |           |              |              |              |
| C            | 339 (56.7)   | 325 (53.6)| 94 (57.3)| 419 (54.4)| 1            | 1            | 1            |
| T            | 259 (43.3)   | 281 (46.4)| 70 (42.7)| 351 (45.6)| 1.13 (0.90–1.42)| 0.98 (0.69–1.38)| 1.10 (0.88–1.36)|
| rs1562444    |              |          |          |           |              |              |              |
| AA           | 133 (44.5)   | 139 (45.9)| 38 (46.3)| 177 (46.0)| 1            | 1            | 1            |
| AG           | 132 (44.1)   | 131 (43.2)| 40 (48.8)| 171 (44.4)| 0.95 (0.68–1.33)| 1.06 (0.64–1.76)| 0.97 (0.71–1.34)|
| GG           | 34 (11.4)    | 33 (10.9)| 4 (4.9)| 37 (9.6)| 0.93 (0.54–1.59)| 0.41 (0.14–1.23)| 0.82 (0.49–1.37)|
| AG+GG        | 166 (55.5)   | 164 (54.1)| 44 (53.7)| 208 (54.0)| 0.95 (0.69–1.30)| 0.93 (0.57–1.52)| 0.94 (0.70–1.28)|
| Allele       |              |          |          |           |              |              |              |
| A            | 398 (66.6)   | 409 (67.5)| 116 (70.7)| 525 (68.2)| 1            | 1            | 1            |
| G            | 200 (33.4)   | 197 (32.5)| 48 (29.3)| 245 (31.8)| 0.96 (0.75–1.22)| 0.82 (0.57–1.30)| 0.93 (0.74–1.17)|

GD, Graves’ disease; HT, Hashimoto’s thyroiditis; AITD, autoimmune thyroid disease (GD + HT); control, control group. OR1, odds ratio 1, GD vs. the control; OR2, odds ratio 2, HT vs. the control; OR3, odds ratio 3, AITD vs. the control; CI, confidence interval.

*[https://doi.org/10.1371/journal.pone.0185529.t002](https://doi.org/10.1371/journal.pone.0185529.t002)*

**Table 3. Combined haplotype frequencies of rs13140012 and rs2119882 in Graves’ disease (GD) and in controls.**

| Total | GD (318) | Control (351) | OR (95% CI) | \( p \) value |
|-------|----------|---------------|--------------|--------------|
| AT    | 0.649    | 0.580         | 1.34 (1.07–1.67) | 0.010 |
| TC    | 0.278    | 0.311         | 0.85 (0.67–1.08) | 0.182 |
| TT    | 0.040    | 0.055         | 0.68 (0.40–1.13) | 0.194 |
| AC    | 0.033    | 0.053         | 0.60 (0.35–1.03) | 0.074 |

OR, odds ratio; CI, confidence interval.

*[https://doi.org/10.1371/journal.pone.0185529.t003](https://doi.org/10.1371/journal.pone.0185529.t003)*
Both rs2119882 and the AATT genotype were retained in the model for predicting GD (Table 4; p = 0.018 and 0.004, respectively). Interestingly, after adjusting for a family history of thyroid disease and smoking, the AA genotype of rs6553010 and AA genotype of rs13140012 were also selected for the regression model for predicting the development of GD (Table 4; p = 0.003 and 0.004, respectively).
p = 0.027 and 0.034, respectively). On the other hand, the AA genotype of rs13140012 was excluded from the regression model for predicting the occurrence of GD in males (p = 0.101).

**Discussion**

In this report, we studied the role of melatonin-MTNRs in AITD by both SNP analyses of clinical specimens and animal studies. We first demonstrated that a genetic variant of MTNR1A, rs2119882, is associated with susceptibility to GD in an ethnic Chinese (i.e., Taiwanese) population. Interestingly, after adjusting for demographic parameters, the AA genotypes of rs6553010 and rs13140012 and the AATT genotypes of rs13140012 and rs2119882 were also likely to be associated with the development of GD. The AA genotype of rs13140012 and TT genotype of rs2119882 were associated with high anti-TPO titers in GD. Meanwhile, the AATT genotypes of rs13140012 and rs2119882 were also correlated with high anti-TPO titers in GD. This evidence supports the involvement of the melatonin-MTNR signal pathway in the pathogenesis of AITD. Thus, our results suggest that subjects with risk alleles, genotypes, or haplotypes of MTNR1A SNPs should avoid stress and smoking or other risk factors to prevent the occurrence of GD. In addition, healthy subjects and GD patients carrying the risk alleles or genotypes should avoid melatonin administration, which might alter the activity of the melatonin-MTNR1A signal pathway, and subsequently induce the development of GD or thyroid dysfunction. We believe that the findings can offer important information in clinical settings.

Previous studies reported that melatonin acts as a modulator of both cell- and antibody-mediated immunity through membrane-bound MTNRs expressed by immune cells, and alterations of the melatonin-MTNR signal pathway might contribute to the development or different clinical phenotypes of autoimmune diseases [17,18,33]. However, in the past, clinical studies that explored associations of MTNRs with autoimmune diseases were limited and only focused on MTNR1B. Ha et al. showed that rs1562444, an SNP of MTNR1B, was not associated with a risk of rheumatoid arthritis, but was correlated with the presence of a rheumatoid factor in rheumatoid arthritis patients [17]. At the same time, Tanev et al. demonstrated that rs10830963 of MTNR1B was not associated with the development of systemic lupus erythematosus but influenced the risk of leukopenia in systemic lupus erythematosus patients [18]. In animal studies, by inhibiting MTNR1A or MTNR1B gene expression, Drazen et al. suggested...

| Genetic variant | Smoking | FH |
|-----------------|---------|----|
|                 | AOR (95% CI) | AOR (95% CI) | AOR (95% CI) |
| rs6553010       |          |      |      |
| AA              | 1        | 1.84 (1.20–2.81)* | 5.74 (3.50–9.42)* |
| AG+GG           | 0.70 (0.50–0.97)* |        |      |
| rs13140012      |          |      |      |
| AA              | 1        | 1.81 (1.19–2.77)* | 5.66 (3.45–9.29)* |
| AT+TT           | 0.70 (0.49–0.96)* |        |      |
| rs2119882       |          |      |      |
| TT              | 1        | 1.79(1.17–2.75)* | 5.62(3.43–9.22)* |
| TC+CC           | 0.67 (0.48–0.93)* |        |      |
| rs13140012/rs2119882 |          |      |      |
| AATT            | 1        | 1.81 (1.18–2.76)* | 5.76 (3.51–9.47)* |
| Non AATT        | 0.61 (0.43–0.85)* |        |      |

* p < 0.05; AOR, adjusted odds ratio; CI, confidence interval; FH, family history of thyroid disease.

https://doi.org/10.1371/journal.pone.0185529.t004
that that MTNR1B was likely to be more essential for promoting melatonin-induced cell-mediated and humoral immunity than was MTNR1A in mice [34]. However, evidence showed that the MT1 receptor is much more abundant than the MT2 receptor in the body. Moreover, the MT1 receptor is extensively distributed in the immune system, including the spleen, thymus, and CD4 and CD8 lymphocytes, while the MT2 receptor was only detected in the thymus, which implies that the MT1 receptor may play a more predominant role in immune regulation than does the MT2 receptor [35,36]. At the same time, melatonin can be synthesized by parafollicular C cells of the thyroid gland, and the MT1 receptor was detectable in the thyroid gland, both of which support our results that genetic variants of MTNR1A could influence susceptibility to AITD development [25,37].

In GD, thyroid autoantibodies other than the TSHRAb, including the anti-TPO Ab and ATA, can be found in the bloodstream. Among these, the anti-TPO Ab is the most common type, with a prevalence of about 75%–90% in GD [38,39]. The production of the anti-TPO Ab or ATA in GD may result from overexpression of TPO and TG by thyroid follicular cells, which is driven by the TSHRAb, and subsequently enhances presentation of these autoantigens to immunocytes and finally promotes the formation of the anti-TPO Ab and ATA (Fig B in S1 File) [40,41]. On the other hand, the presence of the anti-TPO Ab and ATA in GD may also imply a concurrence of GD and HT (Fig B in S1 File) [42]. Actually, in addition to genes that participate in the process of antigen-presenting cell-mediated T-cell activation, increasing evidence shows the importance of B-cell activation in regulating susceptibility to AITD [43]. Recent findings in a study of the role of B-cell activating factor in regulating AITD autoantibody production also support this viewpoint. AITD patients had higher serum B-cell-activating factor levels, and its levels were correlated with TSHRAb levels, anti-TPO Ab levels, and ATA titers in female patients, especially those with active GD [44]. Genetic variants of the B-cell-activating factor also affect the occurrences of GD and AITD, and thyroid autoantibody production [28]. Along with the regulatory effects of melatonin on B-cell-activating factor production [29], the melatonin-MTNR pathway may also exert regulatory actions on B cell activation and autoantibody production. In this study, we found no association of MTNR1A SNPs with TSHRAb levels; thus genetic variants only play an important role in the existence of the TSHRAb and development of GD but not the TSHRAb level (Table 1, Fig A in S1 File). On the contrary, we observed that the AA genotypes of rs13140012 and rs2119882 and the combined AATT genotypes of rs13140012 and rs2119882 of MTNR1A were associated with high anti-TPO Ab concentrations in GD. These findings suggest that genetic variants of MTNR1A might influence the diversity of thyroid autoantibody production in GD, which further supports the notion that the melatonin-MTNR pathway may play a role in modulating B-cell functions, i.e., through regulating the B-cell-activating factor. However, the detailed molecular mechanism underlying these findings is unclear, and further study is needed to investigate the mechanism. Finally, there was no significant association of these SNPs with the severity of GD or HT, which was not a surprising result. Evidence has shown that multiple genes and environmental factors participate in the occurrence and modifications of clinical features and treatment outcomes of GD, and the genetic effect of MTNR1A alone might not be strong enough to affect thyroid function. Moreover, in addition to TSHRAb titers, several clinical parameters, including the age at diagnosis, iodine uptake, and thyroid disease history, could also contribute to the discrepancy in initial thyroid function in GD patients [45].

The human MTNR1A gene was first cloned by Reppert et al., and it encodes the MT1 protein containing 350 amino acids [46,47]. rs2119882 is located in the promoter region, the binding site of transcription factors, and may be associated with MTNR1A gene expression and biological functions [48]. It was reported that hypermethylation of the CpG site in the promoter region in which rs2119882 is located is negatively associated with MTNR1A messenger
(m)RNA expression in oral squamous cell lines [48]. We hypothesized that genetic variants of MTNR1A might modify the function and immunoregulatory activity of MTNR1A and lead to the occurrence of GD. In the present study, we also showed that the AA genotype of both rs13140012 and rs6553010 might also be associated with GD. Both rs13140012 and rs6553010 are located in an intron, which may be associated with splicing of RNA and alterations in MTNR1A mRNA levels. At the same time, it is also possible that rs13140012 is highly associated with the adjacent linked coding region, such as rs2119882 (D’ = 0.80), which is associated with the development of GD. Moreover, using electrophoretic mobility shift assays, Esposito et al. suggested that the T allele of the intronic SNP of rs13140012 could enhance the binding affinity of transcription factors compared to the A allele which modifies MTNR1A gene expression [49]. Further in vitro studies to clarify the biological activities of these SNPs are needed.

In summary, to our knowledge, this is the first report to show a possible association of genetic variants of MTNR1A with susceptibility to GD and diversity in the anti-TPO titer. Results of the genetic study suggest that the melatonin-MTNR pathway could play a significant role in the development and modulation of GD. However, we should indicate certain limitations of the study. First, melatonin levels were not measured in the study, and associations of MTNR1A SNPs with serum melatonin remain to be elucidated. It would be valuable to assess associations among genetic variants of MTNR1A, melatonin levels, and clinical severity. Second, the current study is only a cross-sectional study, and the roles of genetic variants of MTNR1A in determining the remission rate after treatment with an anti-thyroid drug or recurrence rate after discontinuation of medication in GD are unclear. Further well-designed longitudinal studies to assess the genetic effects on remission and recurrence rates of GD are required. Finally, as aforementioned, our results strongly imply that the melatonin-MTNR pathway could be involved in the occurrence and modification of clinical features of GD; however, the actual influence of melatonin in GD was not explored in the present study. It is our future plan to analyze alterations in clinical manifestations, including thyroid function, thyroid autoantibody titers, pathology of the thyroid gland, and thyroid-specific gene expressions after administrating melatonin in a well-established GD animal model to further investigate the role of the melatonin-MTNR pathway in regulating GD.

Supporting information

S1 File. Supplementary figures and tables.

(PDF)

Acknowledgments

We thank all subjects who participated in the study.

Author Contributions

Conceptualization: Chao-Wen Cheng.

Data curation: Shun-Fa Yang, Wen-Fang Fang, Ying-Chin Lin.

Formal analysis: Bing-Chun Liou, Yuh-Feng Lin.

Investigation: Shun-Fa Yang, Bing-Chun Liou, Yuh-Feng Lin.

Supervision: Chao-Wen Cheng.

Writing – original draft: Jiunn-Diann Lin, Chao-Wen Cheng.
References
1. Reiter RJ. Mechanisms of cancer inhibition by melatonin. J Pineal Res 2004; 37: 213–214. https://doi.org/10.1111/j.1600-079X.2004.00165.x PMID: 15357667
2. Malpaux B, Migaud M, Tricoire H, Chemineau P. Biology of mammalian photoperiodism and the critical role of the pineal gland and melatonin. J Biol Rhythms 2001; 16: 336–347. https://doi.org/10.1177/07487301129002051 PMID: 11508379
3. Jimenez-Caliani AJ, Jimenez-Jorge S, Molinero P, Guerrero JM, Fernandez-Santos JM, Martin-Lacave I, et al. Dual effect of melatonin as proinflammatory and antioxidant in collagen-induced arthritis in rats. J Pineal Res 2005; 38: 93–99. https://doi.org/10.1111/j.1600-079X.2004.00175.x PMID: 15683463
4. Manchester LC, Coto-Montes A, Boga JA, Andersen LP, Zhou Z, Galano A, et al. Melatonin: an ancient molecule that makes oxygen metabolically tolerable. J Pineal Res 2015; 59: 403–419. https://doi.org/10.1111/jpi.12267 PMID: 26272235
5. Miller SC, Pandi-Perumal SR, Esquifino AI, Cardinali DP, Maestroni GJ. The role of melatonin in immune-enhancement: potential application in cancer. Int J Exp Pathol 2006; 87: 81–87. https://doi.org/10.1111/j.0959-9673.2006.00474.x PMID: 16623752
6. Cernysiov V, Gerasimcik N, Mauricas M, Girkontaite I. Regulation of T-cell-independent and T-cell-dependent antibody production by circadian rhythm and melatonin. Int Immunol 2010; 22: 25–34. https://doi.org/10.1093/intimm/dxp109 PMID: 19946015
7. Rodriguez IR, Mazuruk K, Schoen TJ, Chader GJ. Structural analysis of the human hydroxyindole-O-methyltransferase gene. Presence of two distinct promoters. J Biol Chem 1994; 269: 31969–31977. PMID: 7999373
8. Pioli C, Caroleo MC, Nistico G, Doria G. Melatonin increases antigen presentation and amplifies specific and non specific signals for T-cell proliferation. Int J Immunopharmacol 1993; 15: 463–468. PMID: 8365822
9. Raghavendra V, Singh V, Shaji AV, Vohra H, Kulkarni A, Agrewala JN. Melatonin provides signal 3 to unprimed CD4(+) T cells but failed to stimulate LPS primed B cells. Clin Exp Immunol 2001; 124: 414–422. https://doi.org/10.1046/j.1365-2249.2001.01519.x PMID: 11472402
10. Lin GJ, Huang SH, Chen SJ, Wang CH, Chang DM, Sytwu HK. Modulation by melatonin of the pathogenesis of inflammatory autoimmune diseases. Int J Mol Sci 2013; 14: 11742–11766. https://doi.org/10.3390/ijms140611742 PMID: 23727938
11. Jimenez-Caliani AJ, Jimenez-Jorge S, Molinero P, Fernandez-Santos JM, Martin-Lacave I, Rubio A, et al. Sex-dependent effect of melatonin on systemic erythematosus lupus developed in Mrl/Mpj-Faslp mice: it ameliorates the disease course in females, whereas it exacerbates it in males. Endocrinology 2006; 147: 1717–1724. https://doi.org/10.1210/en.2005-0648 PMID: 16373423
12. Reppert SM. Melatonin receptors: molecular biology of a new family of G protein-coupled receptors. J Biol Rhythms 1997; 12: 528–531. https://doi.org/10.1177/074873049701200605 PMID: 9406026
13. Fredriksson R, Schioth HB. The repertoire of G-protein-coupled receptors in fully sequenced genomes. Mol Pharmacol 2005; 67: 1414–1425. https://doi.org/10.1124/mol.104.009001 PMID: 15887224
14. Bizzarri M, Proietti S, Cucina A, Reiter RJ. Molecular mechanisms of the pro-apoptotic actions of melatonin in cancer: a review. Expert Opin Ther Targets 2013; 17: 1483–1496. https://doi.org/10.1517/14728222.2013.8215463
15. Morcuende JA, Minhas R, Dolan L, Stevens J, Beck J, Wang K, et al. Allelic variants of human melatonin 1A receptor in patients with familial adolescent idiopathic scoliosis. Spine (Phila Pa 1976) 2003; 28: 2025–2028, discussion 2029.
16. Samimi-Fard S, Abreu-Gonzalez P, Dominguez-Rodriguez A, Jimenez-Sosa A A case-control study of melatonin receptor type 1A polymorphism and acute myocardial infarction in a Spanish population. J Pineal Res 2011; 51: 401–404. https://doi.org/10.1111/j.1600-079X.2011.00903.x PMID: 21635538
17. Ha E, Choe BK, Jung KH, Yoon SH, Park HJ, Park HK, et al. Positive relationship between melatonin receptor type 1B polymorphism and rheumatoid factor in rheumatoid arthritis patients in the Korean population. J Pineal Res 2005; 39: 201–205. https://doi.org/10.1111/j.1600-079X.2005.00237.x PMID: 16088099
18. Taney D, Robeva R, Andonova S, Decheva V, Tomova A, Kumanov P, et al. Melatonin receptor 1B polymorphisms in women with Systemic Lupus Erythematosus. Acta Reumatol Port 2016; 41: 62–67. PMID: 27115109
19. Pang CS, Pang SF. High affinity specific binding of 2-[125I]iodomelatonin by spleen membrane preparations of chicken. J Pineal Res 1992; 12: 167–173. PMID: 1328597
20. Rafii-el-Idrissi M, Calvo JR, Pozo D, Harmouch A, Guerrero JM. Specific binding of 2-[125I]iodomelatonin by rat splenocytes: characterization and its role on regulation of cyclic AMP production. J Neuroimmunol 1995; 57: 171–178. PMID: 7706434

21. Lewinski A, Sewerynek E. Melatonin inhibits the basal and TSH-stimulated mitotic activity of thyroid follicular cells in vivo and in organ culture. J Pineal Res 1986; 3: 291–299. PMID: 3772727

22. Wright ML, Cuthbert KL, Donohue MJ, Solano SD, Proctor KL. Direct influence of melatonin on the thyroid and comparison with prolactin. J Exp Zool 2000; 286: 625–631. PMID: 10766971

23. Wright ML, Pikula A, Babski AM, Labieniec KE, Wolan RB. Effect of melatonin on the response of the thyroid to thyrotropin stimulation in vitro. Gen Comp Endocrinol 1997; 108: 298–305. https://doi.org/10.1006/gcen.1997.6979 PMID: 9356225

24. Gordon J, Morley JE, Herschman JM. Melatonin and the thyroid. Horm Metab Res 1980; 12: 71–73. https://doi.org/10.1055/s-2007-996203 PMID: 7372268

25. Garcia-Marin R, de Miguel M, Fernandez-Santos JM, Carrillo-Vico A, Utrilla JC, Morillo-Bernal J, et al. Melatonin-synthesizing enzymes and melatonin receptor in rat thyroid cells. Histol Histopathol 2012; 27: 1429–1438. https://doi.org/10.14670/HH-27.1429 PMID: 23018242

26. Tomer Y, Davies TF. Searching for the autoimmune thyroid disease susceptibility genes: from gene mapping to gene function. Endocr Rev 2003; 24: 694–717. https://doi.org/10.1210/er.2002-0030 PMID: 14570752

27. Tang XL, Liu XJ, Sun WM, Zhao J, Zheng RL. Oxidative stress in Graves’ disease patients and antioxidant protection against lymphocytes DNA damage in vitro. Pharmazie 2005; 60: 696–700. PMID: 16222871

28. Lin JD, Yang SF, Wang YH, Fang WF, Lin YC, Lin YF, et al. Analysis of Associations of Human BAFF Gene Polymorphisms with Autoimmune Thyroid Diseases. PLoS One 2016; 11: e0154436. https://doi.org/10.1371/journal.pone.0154436 PMID: 27136204

29. Medrano-Camplillo P, Sarmiento-Soto H, Alvarez-Sanchez N, Alvarez-Rios AI, Guerrero JM, Rodriguez-Prieto I, et al. Evaluation of the immunomodulatory effect of melatonin on the T-cell response in peripheral blood from systemic lupus erythematosus patients. J Pineal Res 2015; 58: 219–226. https://doi.org/10.1111/jpi.12208 PMID: 25612066

30. Lin JD, Wang YH, Liu CH, Lin YC, Lin JA, Lin YF, et al. Association of IRF8 gene polymorphisms with autoimmune thyroid disease. Eur J Clin Invest 2015; 45: 711–719. https://doi.org/10.1111/eci.12463 PMID: 25989711

31. Lin FY, Lin CW, Yang SF, Lee WJ, Lin YW, Lee LM, et al. Interactions between environmental factors and melatonin receptor type 1A polymorphism in relation to oral cancer susceptibility and clinicopathologic development. PLoS One 2015; 10: e0121677. https://doi.org/10.1371/journal.pone.0121677 PMID: 25806809

32. Lewontin RC. The Interaction of Selection and Linkage. I. General Considerations; Heterotic Models. Genetics 1964; 49: 49–67. PMID: 17248194

33. Srinivasan V, Spence DW, Trakht I, Pandi-Perumal SR, Cardinaux DP, Maestroni GJ. Immunomodulation by melatonin: its significance for seasonally occurring diseases. Neuroimmunomodulation 2008; 15: 93–101. https://doi.org/10.1159/000148191 PMID: 18679047

34. Drazen DL, Nelson RJ. Melatonin receptor subtype MT2 (Mel1b) and not mt1 (Mel1a) is associated with melatonin-induced enhancement of cell-mediated and humoral immunity. Neuroendocrinology 2001; 74: 178–184. PMID: 11528219

35. Pozo D, Delgado M, Fernandez-Santos JM, Calvo JR, Gomariz RP, Martin-Lacave I, et al. Expression of the Mel1a-melatonin receptor mRNA in T and B subsets of lymphocytes from rat thymus and spleen. FASEB J 1997; 11: 466–473. PMID: 9194527

36. Carrillo-Vico A, Garcia-Pergana A, Najl L, Calvo JR, Romero MP, Guerrero JM. Expression of membrane and nuclear melatonin receptor mRNA and protein in the mouse immune system. Cell Mol Life Sci 2003; 60: 2272–2278. https://doi.org/10.1007/s00018-003-3207-4 PMID: 14618273

37. Garcia-Marín R, Fernandez-Santos JM, Morillo-Bernal J, Gordillo-Martinez F, Vazquez-Roman V, Utrilla JC, et al. Melatonin in the thyroid gland: regulation by thyroid-stimulating hormone and role in thyroglobulin gene expression. J Physiol Pharmacol 2015; 66: 643–652. PMID: 26579570

38. Beever K, Bradbury J, Phillips D, McLachlan SM, Pegg C, Goral A, et al. Highly sensitive assays of autoantibodies to thyroglobulin and to thyroid peroxidase. Clin Chem 1989; 35: 1949–1954. PMID: 2776323

39. Mariotti S, Catureggi P, Piccolo P, Barbiesno G, Pinchera A. Antithyroid peroxidase autoantibodies in thyroid diseases. J Clin Endocrinol Metab 1990; 70: 661–666. https://doi.org/10.1210/jcem-71-3-661 PMID: 2168432

30. Lin JD, Wang YH, Liu CH, Lin YC, Lin JA, Lin YF, et al. Association of IRF8 gene polymorphisms with autoimmune thyroid disease. Eur J Clin Invest 2015; 45: 711–719. https://doi.org/10.1111/eci.12463 PMID: 25989711

31. Lin FY, Lin CW, Yang SF, Lee WJ, Lin YW, Lee LM, et al. Interactions between environmental factors and melatonin receptor type 1A polymorphism in relation to oral cancer susceptibility and clinicopathologic development. PLoS One 2015; 10: e0121677. https://doi.org/10.1371/journal.pone.0121677 PMID: 25806809

32. Lewontin RC. The Interaction of Selection and Linkage. I. General Considerations; Heterotic Models. Genetics 1964; 49: 49–67. PMID: 17248194

33. Srinivasan V, Spence DW, Trakht I, Pandi-Perumal SR, Cardinaux DP, Maestroni GJ. Immunomodulation by melatonin: its significance for seasonally occurring diseases. Neuroimmunomodulation 2008; 15: 93–101. https://doi.org/10.1159/000148191 PMID: 18679047

34. Drazen DL, Nelson RJ. Melatonin receptor subtype MT2 (Mel1b) and not mt1 (Mel1a) is associated with melatonin-induced enhancement of cell-mediated and humoral immunity. Neuroendocrinology 2001; 74: 178–184. PMID: 11528219

35. Pozo D, Delgado M, Fernandez-Santos JM, Calvo JR, Gomariz RP, Martin-Lacave I, et al. Expression of the Mel1a-melatonin receptor mRNA in T and B subsets of lymphocytes from rat thymus and spleen. FASEB J 1997; 11: 466–473. PMID: 9194527

36. Carrillo-Vico A, Garcia-Pergana A, Najl L, Calvo JR, Romero MP, Guerrero JM. Expression of membrane and nuclear melatonin receptor mRNA and protein in the mouse immune system. Cell Mol Life Sci 2003; 60: 2272–2278. https://doi.org/10.1007/s00018-003-3207-4 PMID: 14618273

37. Garcia-Marín R, Fernandez-Santos JM, Morillo-Bernal J, Gordillo-Martinez F, Vazquez-Roman V, Utrilla JC, et al. Melatonin in the thyroid gland: regulation by thyroid-stimulating hormone and role in thyroglobulin gene expression. J Physiol Pharmacol 2015; 66: 643–652. PMID: 26579570

38. Beever K, Bradbury J, Phillips D, McLachlan SM, Pegg C, Goral A, et al. Highly sensitive assays of autoantibodies to thyroglobulin and to thyroid peroxidase. Clin Chem 1989; 35: 1949–1954. PMID: 2776323

39. Mariotti S, Catureggi P, Piccolo P, Barbiesno G, Pinchera A. Antithyroid peroxidase autoantibodies in thyroid diseases. J Clin Endocrinol Metab 1990; 70: 661–666. https://doi.org/10.1210/jcem-71-3-661 PMID: 2168432
40. Weetman AP, McGregor AM, Lazarus JH, Hall R Thyroid antibodies are produced by thyroid-derived lymphocytes. Clin Exp Immunol 1982; 48: 196–200. PMID: 7044629

41. Weetman AP, Cohen S The IgG subclass distribution of thyroid autoantibodies. Immunol Lett 1986; 13: 335–341. PMID: 3781568

42. McLachlan SM, Nagayama Y, Pichurin PN, Mizutori Y, Chen CR, Misharin A, et al. The link between Graves’ disease and Hashimoto’s thyroiditis: a role for regulatory T cells. Endocrinology 2007; 148: 5724–5733. https://doi.org/10.1210/en.2007-1024 PMID: 17823263

43. Lin JD, Cheng CW Causal variants in autoimmune disease: a commentary on a recent published fine-mapping algorithm analysis in genome-wide association studies study. Ann Transl Med 2017; 5(6): 151. https://doi.org/10.21037/atm.2017.02.26 PMID: 28462231

44. Lin JD, Wang YH, Fang WF, Hsiao CJ, Chagnaadorj A, Lin YF, et al. Serum BAFF and thyroid autoantibodies in autoimmune thyroid disease. Clin Chim Acta 2016; 462: 96–102. https://doi.org/10.1016/j.cca.2016.09.004 PMID: 27616625

45. Iglesias P, Devora O, Garcia J, Tajada P, Garcia-Arevalo C, Diez JJ Severe hyperthyroidism: aetiology, clinical features and treatment outcome. Clin Endocrinol (Oxf) 2010; 72: 551–557.

46. Reppert SM, Weaver DR, Ebisawa T Cloning and characterization of a mammalian melatonin receptor that mediates reproductive and circadian responses. Neuron 1994; 13: 1177–1185. PMID: 7946354

47. Slominski RM, Reiter RJ, Schlabritz-Loutsevitch N, Ostrom RS, Slominski AT Melatonin membrane receptors in peripheral tissues: distribution and functions. Mol Cell Endocrinol 2012; 351: 152–166. https://doi.org/10.1016/j.mce.2012.01.004 PMID: 22245784

48. Nakamura E, Kozaki K, Tsuda H, Suzuki E, Pimkhaokham A, Yamamoto G, et al. Frequent silencing of a putative tumor suppressor gene melatonin receptor 1A (MTNR1A) in oral squamous-cell carcinoma. Cancer Sci 2008; 99: 1390–1400. https://doi.org/10.1111/j.1349-7006.2008.00838.x PMID: 18452558

49. Esposito T, Rendina D, Aloia A, Formicola D, Magliocca S, De Filippo G, et al. The melatonin receptor 1A (MTNR1A) gene is associated with recurrent and idiopathic calcium nephrolithiasis. Nephrol Dial Transplant 2012; 27: 210–218. https://doi.org/10.1093/ndt/gfr216 PMID: 21652546